Tumor type and RB1 context may affect exactly how FOXM1 expression influences CDK4/6 inhibitor efficacy, meriting further investigation, but there is growing evidence that FOXM1 plays a key role in determining tumor cell responsiveness and resistance to CDK4/6 targeting. This evidence concerns the gene FOXM1 and neoplasm.